Wedbush raises Opus Genetics stock price target on FDA alignment

Wedbush raised Opus Genetics' (NASDAQ: IRD) price target to $13 from $10 and increased its estimated probability of success for OPGx-BEST1 to 50% from 35% after FDA alignment on potential pivotal-study endpoints. Cohort 2 has enrolled more than eight patients versus a five-patient plan, with dosing expected to finish in Q4 2026 and three-month data due in Q2 2027 to support a sham-controlled pivotal study. Additional analyst targets of $8-$12 and potential approximately $10M Viatris partnership milestone reinforce a favorable clinical and funding outlook, though the stock is up 219% over the past year and may be overvalued.

Analysis

IRD’s rerating is now principally a probability-of-approval trade, not an earnings or cash-flow trade. The revised regulatory framework reduces endpoint-risk at the margin, but tying a functional retinal measure to patient-reported outcomes introduces a separate validation and trial-execution gate; a lower numerical threshold does not establish durable, clinically meaningful benefit. With meaningful efficacy read-through deferred until 2027, the stock is vulnerable over the next 6-12 months to financing needs, enrollment/dosing slippage, or any FDA feedback that narrows acceptable PRO anchoring.

The market is likely underpricing the dilution arithmetic associated with advancing a pivotal gene-therapy program while adding three earlier-stage assets. Any partnership-related non-dilutive proceeds are strategically helpful but unlikely to fund a pivotal program and broader pipeline build-out on their own; cash runway, ATM capacity, and trial-cost guidance matter more than published price targets. VTRS has limited look-through sensitivity: even a modest milestone would be immaterial to its earnings base, so the partnership is not a useful way to express the IRD thesis.

Near term, analyst-target momentum and upcoming data presentations can sustain the tape, particularly in a thinly traded biotech name. The contrarian setup is that the probability increase may already be more than reflected after a 219% trailing-year move: a 50% success probability still implies substantial binary downside, while the next decisive clinical catalyst is distant. A failure of the thesis would be evidence of a fully funded runway through pivotal-study initiation, clean Cohort 2 functional-plus-PRO concordance, and confirmation that the FDA accepts the proposed endpoint package without further qualification.

Key Decisions for Investors

• Do not chase IRD above current levels ahead of a 2027 efficacy catalyst; treat it as a watchlist name until cash runway, quarterly operating burn, and financing alternatives are independently verified.
• For existing IRD holders, trim 25-50% into analyst-driven strength and retain only a small event position sized for binary clinical downside; reassess if the stock breaks materially below the post-update trading range or if a dilutive financing is announced.
• Set a 1-3 month catalyst alert for BIRD-1 presentation details, Cohort 2 dosing progress, and any updated cash guidance. Favor re-entry only if these disclosures extend runway through 2027 without substantial dilution.
• Avoid using VTRS as a long proxy for IRD’s program upside: the economic contribution of a potential milestone is too small relative to VTRS’s diversified earnings base to create favorable beta.
• If listed IRD options have adequate liquidity, consider defined-risk put spreads dated beyond the next corporate-update window rather than an outright short; initiate only after confirming borrow cost and option spreads, as positive FDA clarification could produce another sharp squeeze.